ReviewClinical Medicine Insights. Oncology2023
Understanding Financial Toxicity in Patients with Head and Neck Cancer: A Systematic Review.
Review in Clinical Medicine Insights. Oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- The influence of urban versus rural residence and travel distance on net income, out-of-pocket payments and quality of life in German head and neck cancer survivors.Journal of cancer research and clinical oncology · 2026Article
- Future Inpatient Cost Burden of Laryngeal Cancer in Romania: Aging, Residence, and Prevention Scenarios in a Nationwide Ecological Study.Healthcare (Basel, Switzerland) · 2026Article
- Article
- Longitudinal development and clinical predictors of financial toxicity among radiation oncology patients: final results of the SOCOFIN study.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2026Article
- Web-based dental care information resources for patients with head and neck cancer: a scoping review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Article
- Clinical and social determinants of survivorship clinic attendance in head and neck cancer.Journal of cancer survivorship : research and practice · 2025Article
- Oral Health Characteristics 2 Years following Allogeneic Cell Transplant.Journal of dental research · 2025Observational
- Review
- Social alienation and related factors in patients with head and neck tumors undergoing radiotherapy: a cross-sectional study.BMC nursing · 2025Article
- Financial toxicity in patients with glioblastoma.Journal of neuro-oncology · 2025Article
- National survey of patient perspectives on cost discussions among recipients of copay assistance.The oncologist · 2024Article
- Psychosocial consequences of head and neck cancer symptom burden after chemoradiation: a mixed-method study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Article
- Circulating tumor DNA in head and neck squamous cell carcinoma-current status and future prospects.Academia oncology · 2024Article
- Cancer-associated financial burden in German head and neck cancer patients.Frontiers in oncology · 2024Article
- Pre-Surgical Education and Discharge Planning for Head and Neck Cancer: A Qualitative Study of Patient and Caregiver Perspectives.Cancer control : journal of the Moffitt Cancer CenterArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cancer treatment often results in financial burdens for patients including healthcare costs as well as treatment-induced disability leading to "financial toxicity" (FT) and decreased quality of life. The purpose of this review is to describe FT related to head and neck cancer (HNC) treatment, including quantifications of direct and indirect costs and descriptions of measurement tools. Methods: PubMed, Embase, Cochrane Library, and Web of Science databases were searched to identify articles published before April 2022. Full-text published studies were included if they assessed direct or indirect costs of HNC treatment; studies were excluded if they did not focus on HNC or financial burden. The risk of bias was assessed, and the results of the studies were synthesized. Results: Database searches yielded 530 unique studies, and 33 studies met the criteria for inclusion. Medical expenses for patients with HNC were higher than for patients with other cancers or controls in several studies. Major surgical procedures, neck dissection, free-flap reconstruction, and intensive care unit admission increased hospital costs. Trimodal therapy with surgery plus chemoradiation represented the most expensive treatment, and chemoradiation increased complication-related health care costs. In several studies, >50% of patients treated for HNC were disabled and did not return to work. One of the greatest contributors to the indirect cost of HNC treatment is the loss of lifetime wages. Patients with HNC are at risk for depression, anxiety, and social isolation, which are linked to a decreased quality of life and treatment non-adherence. The only tools used to assess FT in patients with HNC are the Comprehensive Score for financial Toxicity (COST) and the Financial Index of Toxicity (FIT). Conclusion: Financial toxicity is highly prevalent among patients with HNC. Further research is needed to validate the assessment tools for quantifying FT in HNC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.